ALVAL Share Price Performance
€0.71
-0.91 (-56.16%)
Price €0.71
Share Pricen/a
Does Valbiotis (EPA:ALVAL) Have A Healthy Balance Sheet?
Nov 19
Valbiotis SA Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
ALVAL Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Valbiotis SA Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- -0.47
- -394.94%
- -2,344.94%
- 35.9%
About ALVAL
- Founded
- 2014
- Employees
- 44
- CEO
- WebsiteView website
Valbiotis SA engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France. The company offers Lipridrivea for the treatment of hypercholesterolemia. It develops TOTUM-63 for the reduction of fasting blood glucose and treatment of type 2 diabetes; TOTUM-854, which is in Phase II/III clinical trials for reducing systolic blood pressure; and TOTUM-448 for the reduction of hepatic steatosis. The company has a partnership with Leiden University, Vanderbilt University, INAF, CarMeN Laboratory, LAPEC, MEDiS Unit, M2iSH, Clermont-Ferrand Clinical Investigation Center, ADECAL, and IFREMER. Valbiotis SA was incorporated in 2014 and is based in Périgny, France.
